While Ruxolitinib (JAK1/JAK2 inhibitor) impaired murine CTL activity against tumor cells in vitro, neither pacritinib (JAK2 inhibitor) nor ruxolitinib interfered with the GVL effect in vivo in MHC-mismatched murine models (186, 194). Here, JAK2 is linked to neoplasm.